Argent BioPharma Limited (ASX:RGT)
Australia · Delayed Price · Currency is AUD 0.0320
+0.0020 (6.67%)
Sep 4, 2026, 3:58 PM AEST
Argent BioPharma Revenue
In the fiscal year ending June 30, 2026, Argent BioPharma had annual revenue of 161.19K AUD, down -10.73%. Argent BioPharma had revenue of -10.31K in the half year ending June 30, 2026.
Revenue
161.19K
Revenue Growth
-10.73%
P/S Ratio
23.15
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 161.19K | -19.38K | -10.73% |
| Jun 30, 2025 | 180.57K | -710.52K | -79.74% |
| Jun 30, 2024 | 891.08K | -2.50M | -73.70% |
| Jun 30, 2023 | 3.39M | -1.34M | -28.41% |
| Jun 30, 2022 | 4.73M | 1.74M | 57.94% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vitura Health | 131.16M |
| ECS Botanics Holdings | 21.02M |
| IDT Australia | 20.38M |
| Elixinol Wellness | 15.28M |
| Epsilon Healthcare | 13.58M |
| Peak Processing | 12.51M |
| Cann Group | 9.65M |
| Syntara | 6.93M |
Argent BioPharma News
- 1 year ago - Argent BioPharma Enters Germany - Europe's Largest Market - PRNewsWire
- 1 year ago - Argent BioPharma Expands Pipeline with Promising Drug CimetrA® - PRNewsWire
- 1 year ago - Argent BioPharma Ltd. Updates on SINTEF Collaboration for Chronic Wound Management - PRNewsWire
- 1 year ago - Argent BioPharma Ltd. Raised US$4,500,000 - PRNewsWire
- 1 year ago - Argent BioPharma Ltd. Placing to Raise US$4,500,000 - PRNewsWire